logo-loader

Zynerba Pharmaceuticals shares skyrocket on cannabis-based drug trial success

Last updated: 15:00 28 Sep 2017 EDT, First published: 10:00 28 Sep 2017 EDT

1506625480_shutterstock_234586750

RISERS

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) saw shares shoot up over 55% to US$9.61 as it reported top line results in cannabidiol gel ZYN002 open label phase 2 study in children with Fragile X syndrome. The study successfully met the primary endpoint.

The firm is a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced cannabinoid treatments.

Exa Corp  (NASDAQ:EXA) added almost 41% at US$24.25  after Dassault Systèmes announced plans to acquire the group for $24.25 per share in cash.

FALLERS

GoPro Inc (NASDAQ:GPRO) shares shed 1.72% to US$11.49 as  the firm confirmed the release of Hero 6 and GoPro Fusion. The company hopes the new cameras will lead to strong holiday season sales.

Ramp Metals Launches Drilling Program in Pursuit of High-Grade Nickel in...

Ramp Metals CEO Jordan Black joined Steve Darling from Proactive to introduce the company to the public domain and share exciting developments in the mining industry. With a background as a geotechnical engineer and experience in venture capital, including a notable role in taking GoldSpot...

47 minutes ago